# Hims & Hers launches new peptide treatments — while admitting there’s more to learn about efficacy

- URL: https://talkfuse.com/story/hims-hers-launches-new-peptide-treatments-while-admitting-theres-more-to-learn-about-efficacy/
- Published: 2026-11-18T14:02:52+00:00
- Updated: 2026-11-19T00:10:12+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html
- Topics: Business, Companies, Health, Medicine

## Key points

- Hims & Hers has introduced five compounded peptide and longevity formulations.
- None of the specific products is FDA-approved.
- The company says more research is needed on effectiveness.

## Summary

Hims & Hers has launched five compounded peptide and longevity formulations through its Peptides+ platform, entering a fast-growing market where products are promoted for recovery, fitness and anti-ageing. The company says there is still more to learn about how the peptides should be used and how effective they are, reflecting the limited evidence from robust human trials.

The initial range includes sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine; none of these specific compounded products is approved by the US Food and Drug Administration. Hims said more than 10,000 people joined its early access list within 15 days and plans to add BPC-157 and TB-500, for which most research has been conducted in animals. The rollout follows the easing of federal restrictions on compounding certain unapproved peptides.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
